H3K27M Diffuse Midline Glioma Is Homologous Recombination Defective and Sensitized to Radiotherapy and NK Cell-Mediated Antitumor Immunity by PARP Inhibition

Homologous recombination repair deficiency in histone H3 lysine 27-to-methionine diffuse midline glioma (H3K27M DMG) can be therapeutically leveraged with PARP inhibitors to radiosensitize and induce an NK cell-mediated antitumor immune response selectively in H3K27M DMG, supporting the clinical investigation of PARP1 inhibitors with radiotherapy in DMG patients.